JPH0224544B2 - - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing a urinary catheter having the ability to prevent urinary tract infections and is made of an olefinic polymer, a diene polymer, or a silicone polymer.

Patients with spinal cord injury, cerebral hemorrhage, encephalomalacia, or surgery are often accompanied by symptoms such as difficulty urinating and urinary incontinence. In such cases, urinary catheterization using a catheter is used to ensure a smooth urinary tract, thereby promoting maintenance or improvement of renal function or preventing urine leakage. The catheter used in this case is particularly called a urinary catheter.
For its intended use, it is required to have sufficient flexibility, elasticity, and harmlessness to the human body, and most of them are made from olefin polymers, diene polymers, or silicone polymers.

Urinary catheterization is an extremely useful treatment method that allows prompt urination, and is therefore frequently used not only in urology but also in fields such as surgery, internal medicine, and obstetrics and gynecology. However, once a urinary catheter is placed in the urinary tract, infection is inevitable. That is, since the urinary catheter is left in the urinary tract for a long time, bacteria can enter through the catheter, and symptoms such as urethritis, cystitis, and pyelitis frequently occur. When the conventional open continuous catheterization method (a method of collecting urine in an unsterilized container such as a glass bottle) was performed, infection occurred in 42-80% of cases within 3 days.
It has been reported that infection was established in all cases on the seventh day.

For this reason, methods such as cleaning the bladder and injecting disinfectants have been used to prevent urinary tract infections, but these procedures are cumbersome and are inconvenient as they can become a source of new infections. There are many faces.

Chemotherapy, such as prophylactic administration of antibacterial substances, is also used, but there are problems with side effects that occur frequently even with small doses depending on the type of antibacterial substance or large doses, and bacterial replacement once an infection occurs. Local use of antibacterial substances is strongly desired, to the extent that unplanned chemotherapy is said to be harmful due to problems such as the ease with which antibiotics can develop.

Regarding the topical use of antibacterial substances, there are methods such as applying an ointment containing antibacterial substances to the urinary catheter, or coating the wall with resin and using this coating layer with antibacterial substances (Special Publications in 1973).
-27680), but with these methods, the antibacterial substance is simply adsorbed to the support layer, so the antibacterial substance is washed away by urine and leaves the body within a very short period of time after indwelling. It cannot be used satisfactorily because it leaks and its antibacterial function is no longer recognized.

In addition, a method of instilling diluted antibacterial solution directly into the bladder using a so-called three-way catheter is also used as a local treatment method, but it is difficult and cumbersome to handle, so it is not recommended in some urology departments. The current situation is that it has only been adopted and is not used in other clinical areas.

Bacterial invasion routes include retrograde entry through the gap between the urinary catheter and the urinary tract mucosa (extraluminal route), invasion from the joint between the urinary catheter and the duct (including procedures such as cleaning), and entry from the urinary storage area into the duct and the urinary duct. There is retrograde movement inside the urinary catheter (intraluminal route). In the case of invasion through the extraluminal route, normal pressure bacteria of the urethra quickly ascend along the wall of the urinary catheter in the early stage after placement.
reaches the bladder neck. Against such infections, the antibacterial substances present on the wall of the urinary catheter can exert an antibacterial function because they can come into direct contact with bacteria. However, bacteria that enter through the intraluminal route, such as through the urinary collector, that is, fall into or enter the urinary collector, multiply in the collected urine and reach the bladder meat as the urine flows backward and air bubbles rise. . actual,
In static experiments, it has also been confirmed that bacteria travel upstream in the urine like a carp climbing a waterfall. In case of invasion from such a route, the antibacterial substances present on the wall of the urinary catheter may not be able to come into direct contact with the bacteria, so there is a high possibility that bacteria that cannot be affected by the antibacterial function will remain. The ability to prevent infection is not sufficient. In order to have the ability to prevent infection from all entry routes, antibacterial substances must not only exist on the wall of the urinary catheter, but also gradually leave the wall and diffuse into the urine. It is necessary to come into contact with bacteria that float upward. In this case, the speed at which the antibacterial substance leaves the wall surface becomes an issue.
As mentioned above, if methods such as adsorbing antibacterial substances on the urinary catheter, applying ointment containing antibacterial substances, or coating the wall with resin and impregnating this coating layer with antibacterial substances are used. During this period, antibacterial substances are easily washed away by urine, leaving the body, and are no longer present on walls or in urine in an extremely short period of time. This means that the ability to prevent infection is completely lost after being left in the body for an extremely short period of time. Therefore, it is important to control the rate at which antibacterial substances leave the wall surface and to maintain the concentration of antibacterial substances in urine above an effective concentration over a long period of time in order to prevent infection.

In view of the current situation, the present inventors developed a urinary catheter that is easy to use, does not become a new source of infection, and has the ability to prevent infection from all entry routes over a long period of time. As a result of extensive research with the aim of providing They discovered that the antibacterial substance gradually separates from the reaction product, and successfully applied this phenomenon to urinary catheters, resulting in the present invention.

That is, the present invention provides an inner or outer wall of a urinary catheter made of an olefinic polymer, a diene polymer, or a silicone polymer,
(A) Copolymer of maleic anhydride and an aromatic vinyl monomer or olefin monomer copolymerizable with maleic anhydride [hereinafter abbreviated as component (A)]. ] 0.5 to 99.5 parts by weight and (B) a copolymer of maleic anhydride and an aliphatic vinyl ether or aliphatic vinyl ester copolymerizable therewith [hereinafter abbreviated as component (B). 〕0.5～99.5
1 to 200 parts by weight of polyfunctional compound (C) per 100 parts by weight of the total amount of components (A) and (B) [hereinafter (C)
Abbreviated as ingredient. ) to form a film containing unreacted maleic anhydride groups on the inner or outer wall, and then, after hydrolyzing some or all of the maleic anhydride groups, an antibacterial substance is bonded to the film. This is a method for manufacturing a urinary catheter having the ability to prevent urinary tract infection.

The olefinic polymer referred to in the present invention refers to a hydrocarbon having one double bond, such as ethylene, propylene, 1-butene, 3-methyl-1-butene, 3,3-dimethyl-1-butene, 1 -Pentene, 4-methyl-1-pentene, 3-methyl-1
-Pentene, 1-hexene, 4-methyl-1-hexene, 5-methyl-1-hexene, 1-heptene, 1-octene, 1-decene, 1-hexadecene, 1-octadecene, vinylcyclopropane,
Vinylcyclohexane, isobutylene, 2-methyl-1-pentene, cyclobutene, norbornene, etc. are monopolymerized or copolymerized by a known method.

The diene polymer referred to in the present invention is a hydrocarbon having two double bonds, such as butadiene, isoprene, 1,3-pentadiene, 1,5-hexadiene, 1,6-heptadiene, etc. Or it refers to a copolymerized material. As an exception, cis-1,4-polymers of isoprene, which are widely found in nature as natural rubber, are also preferably utilized in the present invention.

Other copolymerization components include vinyl acetate, methyl vinyl ether, styrene, vinyl chloride, vinylidene chloride, maleic anhydride, acrylic acid, methacrylic acid, acrylonitrile, methyl methacrylate, sulfur dioxide, vinylpyridine, chloroprene, ethylene oxide, Examples include formaldehyde.

Examples of silicone polymers used in the present invention include dimethylpolysiloxane, methylphenylpolysiloxane, cyanoalkylmethylpolysiloxane, and fluoroalkylmethylsiloxane, which have high elasticity, high strength, and are harmless to the human body. From this point of view, dimethylpolysiloxane is particularly preferred.

As component (A) used in the present invention, any copolymer of maleic anhydride and an aromatic vinyl monomer or olefin monomer that can be copolymerized therewith can be used, but maleic anhydride is preferable. and styrene or ethylene or isobutylene or polypropylene are used, particularly preferably copolymers of maleic anhydride and the monomers mentioned above, in a copolymerization ratio of 1:1.
~1:5 and a molecular weight of 500 to 2,000,000 is used.

As component (B) used in the present invention, any copolymer of maleic anhydride and an aliphatic vinyl ether or aliphatic vinyl ester that can be copolymerized with maleic acid can be used, but anhydrous is preferably used. Copolymers of maleic acid and vinyl acetate or methyl vinyl ether or ethyl vinyl ether or butanediol vinyl ether are used, particularly preferably copolymers of maleic anhydride and the monomers mentioned above, in a copolymerization ratio of 1:1 to
1:5 and a molecular weight of 500 to 2,000,000 is used. Component (C) used in the present invention includes polyisocyanates such as hexamethylene diisocyanate, toluene diisocyanate, xylene diisocyanate, phenylene diisocyanate, isocyanate derivatives of aniline-formaldehyde, and hexamethylene diisocyanate. Polythioisocyanate such as nerat, polyepoxide such as tetramethylene glycol, glycidyl ether, diglycidyl ether of diethylene glycol, polyvinyl alcohol, copolymer of polyvinyl alcohol with ethylene, propylene, vinyl chloride, allyl alcohol, N-vinylpyrrolidone, etc. , polyvinyl alcohol methyl, ethyl,
Ether derivatives such as propyl, butyl, octyl, dodecyl, and phenyl, formal polyvinyl alcohol, acetal derivatives such as ethanal, butyral, and aminoacetal, acetic acid, formic acid, butyric acid, caproic acid, lauric acid, stearic acid, and benzoic acid of polyvinyl alcohol. ester derivatives such as ethylene glycol, propylene glycol, butylene glycol, diethylene glycol, cyclohexanediol, pentaerythritol, glycerin, polyols such as 1,1,1-trimethylolpropane and their carboxymethylated products, polyethylene glycol, polypropylene glycol, polytetra Polyether polyols such as methylene glycol, polyethylene-polypropylene glycol, and their carboxymethylated products, dicarboxylic acids such as succinic acid, glutaric acid, adipic acid, sebacic acid, isophthalic acid, phthalic acid, and terephthalic acid, and ethylene glycol, propylene glycol, butylene Polyesters with hydroxyl groups at both ends obtained by condensation with glycols such as glycols and their carboxymethylated products, natural polymers such as starch, gelatin, dextran and their carboxymethylated products, monoethanolamine, triethanolamine, etc. Examples include amino alcohols and polyamines. As the polyamine, for example, ethylenediamine as a low molecular polyamine,
Trimethylene diamine, 1,2-diaminopropane, tetramethylene diamine, 1,3-diaminobutane, 2,3-diaminobutane, pentamethylene diamine, 2,4-diaminopentane, hexamethylene diamine, octamethylene diamine, nonamethylene Diamine, decamethylenediamine, undecamethylenediamine, dodecamethylenediamine, tridecamethylenediamine, octadecamethylenediamine, N,N-dimethylethylenediamine, N,N-diethyltrimethylenediamine,
N,N-dimethyltrimethylenediamine, N,N
-dibutyltomethylenediamine, N,N,N'-
Triethylethylenediamine, N-methyltrimethylenediamine, N,N-dimethyl-p-phenylenediamine, N,N-dimethylhexamethylenediamine, diethylenetriamine, triethylenetetramine, tetraethylenepentamine, heptaethyleneoctamine, nonaethylenedecamine Min,
1,3-bis(2'-aminoethylamino)propane, bis(3-aminopropal)amine, 1,3
-bis(3′-aminopropylamino)propane,
1,2,3,-triaminopropane, tris(2
-aminoethyl)amine, tetra(aminomethyl)methane, methyliminobispropylamine,
Methyliminobisethylamine, ethyliminobisethylamine, N-aminopropyl-2-morpholine, N-aminopropyl-2-pipecoline, N
-(2-hydroxyethyl)trimethylenediamine, xylylenediamine, phenylenediamine,
piperazine, N-methylpiperazine, N-(2-
(aminoethyl) ethanolamine, N-aminoethylpiperazine, N,N,N',N'-tetramethylethylenediamine, N,N,N',N'-tetramethyltetramethylenediamine, etc.
As a polymeric polyamine, (i) poly(alkylene polyamine) synthesized from amine and alkylene dihalide or epichlorohydrin [Encyclopedia. of Polymer Science and Technology, (Encyclopedia of Polymer
(ii) Alkyleneimine polymers obtained by ring-opening polymerization of alkyleneimines such as ethyleneimine and propyleneimine [Encyclopedia of Polymer Science and Technology], Volume 10, Page 616] technology, 1
Volume, page 734], (iii) Others include polyvinylamine, polylysine, etc. Among these, polyvinyl alcohol, its derivatives, polyols, and polyether polyols are preferably used from the viewpoint of biocompatibility and nontoxicity. It will be done.

The antibacterial substance referred to in the present invention refers to antibiotics and bactericidal agents. Examples of antibiotics include penicillins such as cloxacillin, dicloxacillin, flucloxacillin, ampicillin, hetacillin, talampicillin, cyclacillin, amoxicillin, pivmecillinum, and piperacillin, cephalolidine, cephaloglycine, cephalexin,
Cephalosporins such as cefazoline, cefapirin, cefrazine, ceftesol, cefoxitin, and cephatridine; aminoglycosides such as streptomycin, kanamycin, fradiomycin, paromomycin, gentamicin, bekanamycin, ribostamycin, dibekacin, amikacin, tobramycin, and spectinomycin; oxytetracycline; , tetracyclines such as tetracycline, dimethylchlortetracycline, methacycline, doxycycline, and minocycline; macrolides such as erythromycin, kitasamycin, oleandomycin, spiramycin, diyosamycin, and midecamycin; lincomycins such as lincomycin and clindamycin. , antigram-positive bacteria such as micamicin, gramicidin S, and gramicidin, polymyxins such as colistin and polymyxin B, antimycobacteria such as biomycin, capreomycin, enviomycin, and cycloserine, amphotericin B, pimaricin, etc. polyene macrolides,
Examples include rifampicin, pyrrolnitrin, mitomycin C, actinomycin, bleomycin, daunorubicin, doxorubicin, and neocarzinostatin, but aminoglycosides are preferred because of their strong basicity and high efficacy against bacteria that cause urinary tract infections. Alternatively, polymyxins are preferably used. Disinfectants include pigment preparations such as acrinol and acrylflavin, furan preparations such as nitrofurazone, and positive soap preparations such as benzalkonium chloride and benzathonium chloride.
Cyclohexidine, povidone iodine and the like are preferably used.

To manufacture a urinary catheter by the method of the present invention, first, components (A), (B), and (C) are reacted on the inner or outer wall of the catheter to form a coating on the inner or outer wall. It is necessary to form a For this purpose, for example, components (A), (B), and (C) may be mixed using an organic solvent as a medium, the inner or outer wall of the catheter may be brought into contact with this solution, and then the catheter may be heated. Examples of methods for mixing the three components include mixing a solution of component (A), a solution of component (B), and a solution of component (C);
What order and method should be used, such as adding component (C) to a solution obtained by adding a solvent to component (B), or adding a solvent to a mixture of components (A), (B), and (C)? But it is possible. In order to enhance the mixing effect and shorten the mixing time, it is desirable to heat or stir as necessary. Examples of organic solvents that can be used in the present invention include ketones such as acetone and methyl ethyl ketone, aldehydes such as benzaldehyde, formaldehyde, and dimethyl formaldehyde, ethers such as tetrahydrofuran, esters such as methyl acetate and ethyl acetate, methanol, and ethanol. Examples include alcohols such as , propanol, isopropanol, and butanol, but ketones and alcohols are preferably used. The solution thus prepared can be brought into contact with the inner or outer wall of the catheter, for example by dipping the catheter in the solution or by spraying the solution onto the catheter or by applying it, for example with a doctor's knife or a "brush". You can choose any method as appropriate. After contacting the catheter with the solution in this way, the solvent is dried and removed,
Then preferably 30~180℃, particularly preferably
Components (A), (B), and (C) are reacted by heating at 50 to 160°C for preferably 5 minutes to 48 hours, particularly preferably 10 minutes to 24 hours, and the inner or outer wall of the catheter is heated. A film can be formed thereon. The ratio of component (A), component (B), and component (C) to be reacted on the inner or outer wall of the catheter is 0.5 to 99.5 parts by weight of component (A) and 0.5 to 99.5 parts by weight of component (B). , (C) component is the total amount of (A) component and (B) component 100
The amount is 1 to 200 parts by weight. (A) Ingredients and (B)
The ratio of component (A) to the total amount of components is 0.5% by weight
If the amount is less than 99.5% by weight, the solubility of the obtained film in urine is too high and the film will dissolve during long-term indwelling in the body.On the other hand, if it exceeds 99.5% by weight, the ability to bind antibacterial substances will be significantly reduced. The proportion of component (A) should be 0.5 to 0.5.
99.5% by weight, preferably 20-99.5% by weight, particularly preferably 30-95% by weight.
If the ratio of component (C) to 100 parts by weight of the total amount of components (A) and (B) is less than 1 part by weight, urine may be removed depending on the type or blending ratio of components (A) and (B). The solubility for 200
If the proportion of component (C) exceeds 1 part by weight, not only the ability of the obtained film to bind antibacterial substances will be significantly reduced, but also the film forming property will be poor.
It is necessary to use 200 parts by weight, preferably 1 to 150 parts by weight, particularly preferably 20 to 100 parts by weight.

In the present invention, it is necessary to leave unreacted maleic anhydride groups in the film formed on the inner or outer wall of the catheter. For this purpose, for example, the ratio of the maleic anhydride used in the reaction to the functional group of the component (C), the reaction temperature, and the reaction time may be adjusted as appropriate. By adjusting them, a desired amount of unreacted maleic anhydride groups can be left in the film formed on the inner or outer wall.

In the present invention, it is then necessary to hydrolyze some or all of the maleic anhydride groups in the film obtained as described above. Hydrolysis can be performed, for example, on a membrane-formed catheter for 10 to 10 minutes.
This is achieved by immersion in water at 100°C, preferably 40 to 100°C, for about 5 minutes to 48 hours, preferably about 1 to 10 hours.

In the present invention, it is then necessary to bond an antimicrobial substance to the film treated as described above. The antibacterial substance can be bound to the membrane by, for example, forming the antibacterial substance into a solution, preferably an aqueous solution, and spraying this solution onto the catheter; circulating this solution within the catheter;
A method such as dipping the catheter in this solution can be adopted. The binding of the antibacterial substance is preferably carried out at a temperature of -10 DEG to 60 DEG C., particularly preferably 0 DEG to 50 DEG C., for a few seconds to 72 hours, preferably for 5 minutes to 48 hours.

The urinary catheter produced by the method of the invention has properties ideal for preventing urinary tract infections. In other words, the period during which a urinary catheter is left in the body is most often 3 to 5 days.
In the longest case, the catheter is left in place for about two weeks, and in very rare cases it is left in place for about five weeks.The urinary catheter manufactured by the method of the present invention gradually deteriorates over such a period of time. It has the ideal property of releasing antibacterial substances into the urine. Furthermore, it has ideal characteristics regarding the amount of release. In other words, until about the 5th day after catheter insertion, that is, the period when the infection rate is particularly high due to the resident bacteria of the urethra that are pushed into the bladder along with the catheter at the time of catheter insertion (if the catheter is inserted for such a period, clinical (which is the most common), a large amount is released, and although the amount released temporarily decreases thereafter, it has the characteristic that even after 5 weeks, a sufficient amount is released to prevent urinary tract infections. Although this characteristic of showing a temporary decrease is not necessarily necessary from the perspective of preventing urinary tract infections, from an economic perspective, it does not require the use of more antibacterial substances than necessary. This is an advantageous and desirable characteristic, considering that it is less likely that the ability to prevent infection will be diminished due to the emergence of resistant bacteria due to repeated use of large amounts, which can occur when using antibiotics. This can be said to be an ideal characteristic for a urinary catheter. This will be explained more specifically by giving an example as follows.

A urinary catheter bound to an aminoglycoside antibiotic produced by the method of the present invention was immersed in a certain amount of urine at 37°C, and the procedure was performed by replacing the urine with the same amount of fresh urine every day for 40 days. 40 urine samples were obtained and the amount of antibiotics contained in each sample was determined.
The amount of antibiotics in the urine on the first day was in the range of 1,500 to 40,000 μg, and on the second day it was 1,000 to 35,000 μg.
750-25000μg on day 500-25000 on day 4-5
20000μg, 6-7 days 250-15000μg, 8-10
Day 250-10000μg, 11th-14th day 250-7500μg
g, 150-5000 μg on days 15-30, and 150-5000 μg on days 31-40.
The amount was 100 to 2500 μg. As mentioned above, the amount released on days 1 to 5 is large, with the lowest case being over 500 μg, and up to day 14 over 250 μg is released, and the ability to prevent infection even on days 31 to 40. The amount released is such that it is considered to have a

In the present invention, component (A), component (B), and (C) are used.
Depending on the type of components and the material of the urinary catheter, adhesive may be used as necessary to attach the catheter to the film made of the reaction product of components (A), (B), and (C). It is possible to glue it. Adhering methods include, for example, providing a layer of adhesive on the inner or outer wall of the catheter in advance and reacting each component on the surface of this layer, or mixing the adhesive into a mixture of each component in advance. etc. can be adopted.

The present invention will be explained in more detail with reference to Examples below. Note that "parts" in the examples mean "parts by weight."

Example 1 1 part of Gantrez AN169 (manufactured by GAF, copolymer of methyl vinyl ether and maleic anhydride),
1 part of SMA3000 (manufactured by ARCO Chemical, copolymer of styrene and maleic anhydride) and magrogol
400 (manufactured by Matsumoto Yushi Co., Ltd., polyethylene glycol) 1
A silicone urinary catheter (Argyle Silicone Foley Catheter, manufactured by Nippon Schatz Co., Ltd.) was immersed in a solution of 27 parts of acetone at room temperature for 3 minutes, and then removed at 60°C.
The catheter was dried for 2 hours at 140° C. and further heat-treated for 5 hours at 140° C. to obtain a catheter having a film made of a reaction product of GantreZ, SMA, and magrogol on the inner and outer walls. The catheter obtained in this way was
After soaking in water at 7°C for 2 hours, it was taken out and air-dried, and then dibekacin sulfate aqueous solution [150mg (potency)/100ml] was soaked at 7°C while adjusting the pH to 8 using 0.1N sodium hydroxide. After soaking for a period of time, a dibekacin sulfate-bound catheter was obtained.

This material was immersed in test urine at 37°C under sterile conditions.
After one day, Bacillus Subtilis was detected in the test bacteria.
When testing the antibacterial activity of this urine by dropping 2 to 3 drops of test urine onto a cylindrical plate using ATCC6633 using the cylindrical plate method, an inhibition circle was generated, indicating the presence of active antibiotics in the test urine. was confirmed. Furthermore, when the same active strike was repeated by replacing the test urine with new test urine every day, it was confirmed that the test urine collected on the 40th day also produced an inhibition zone and had activity.

Furthermore, the amount of dibekacin sulfate released in the test urine obtained as described above was measured using a color quantitative method using sodium P-naphthoquinone-4 sulfonate.
28000μg, 23000μg on the 3rd day, 10000μg on the 5th day
g, 7500 μg on the 7th day, 5000 μg on the 14th day, and 1000 μg on the 35th day.

Comparative Example 1 The same test as in Example 1 was conducted on a catheter obtained in exactly the same manner as in Example 1, except that the operation of immersing it in water at 70°C for 2 hours was not performed, and no inhibition circle was generated. Ta.

Comparative example 2 2 parts of Gantrez AN169 and 1 part of tuna gor
A catheter bound to dibekacin sulfate was obtained in exactly the same manner as in Example 1, except that a solution prepared by dissolving 400 in 27 parts of acetone was used. When this product was subjected to the same test as in Example 1, dissolution of the film was observed from about the 10th day, and it was judged to be unsuitable for actual application.

Comparative example 3 2 parts SMA3000 and 1 part Tuna Gol 400 at 27
The coating of a catheter obtained in exactly the same manner as in Example 1 except that a solution in which the above-mentioned components were dissolved in acetone was used was poor in uniformity. Further, when this product was used to bind dibekacin sulfate in the same manner as in Example 1 and the same test as in Example 1 was conducted, no inhibition zone was produced in the test urine on the 5th day.

Examples 2-4 5 parts Gantrez AN169 and 95 parts SMA3000 and 30
Three catheters obtained in the same manner as in Example 1 except for using a solution of 1 part triethylene glycol dissolved in 900 parts acetone were immersed in water at 60°C for 4 hours, and one catheter was immersed in a gentamicin aqueous solution [ 150mg
(potency)/100ml] and add another bottle of Polymyxin B.
Add the remaining bottle to the aqueous solution [1 million units/100ml] and add the remaining bottle to the fradiomycin aqueous solution [150mg (potency)/100ml]
It was immersed in water for 2 hours at 25°C. When the same test as in Example 1 was conducted on the three catheters after soaking using test bacteria corresponding to each antibiotic, test urine obtained from all catheters on the 40th day showed an inhibition zone. .

Example 5 1 part of a copolymer of maleic anhydride and ethylene (copolymerization ratio 1:1, molecular weight 500,000) and a copolymer of maleic anhydride and ethyl vinyl ether (copolymerization ratio 1:1)
1. A solution prepared by dissolving 1 part (molecular weight: 500,000) and 0.5 part of polyvinyl alcohol with a degree of saponification of 99.9 mol% and a degree of polymerization of 1700 in 10 parts of acetone was added to a natural rubber urinary catheter [Argyle Foley Catheter, manufactured by Nihon Sha Wood Co., Ltd.]. ] using a peristaltic pump at room temperature for 3 hours at a rate of 5 ml/min, dried at 80°C for 1 hour, and then heat-treated at 150°C for 6 hours to form a film on the inner wall of the catheter. was formed. The catheter thus obtained was immersed in water at 60°C for 5 hours, taken out and air-dried, and then immersed in a 1 wt% aqueous solution of acrinol for 2 hours at room temperature to obtain a catheter bound with acrinol. . When the same test as in Example 1 was conducted using the obtained catheter, 40
Test urine on day 1 produced an inhibition zone.

Claims (1)

[Claims] 1. In the inner or outer wall of a urinary catheter made of an olefin polymer, a diene polymer, or a silicone polymer, (A) a copolymer of maleic anhydride and an aromatic vinyl monomer or an olefin monomer that can be copolymerized with maleic anhydride. 0.5 to 99.5 parts by weight of a polymer, (B) 0.5 to 99.5 parts by weight of a copolymer of maleic anhydride and an aliphatic vinyl ether or aliphatic vinyl ester copolymerizable therewith, component (A) and B.
1 to 200 parts by weight of (C) per 100 parts by weight of the total amount of ingredients
A film having unreacted maleic anhydride groups is formed on the inner or outer wall by reacting with a polyfunctional compound, and then some or all of the maleic anhydride groups are hydrolyzed, and then the film is treated with antibacterial agents. A method for producing a urinary catheter having the ability to prevent urinary tract infection, the method comprising binding a substance.